XERS

Xeris Biopharma Holdings

5.60

+0.20+3.70%

Closed19:51 03/30 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE5.32/5.40

TODAY RANGE5.29-5.64

VOL2.54M

MARKET CAP965.62M

52 WEEK RANGE3.805-10.08

AVG VOL (3M)2.03M

% TURNOVER1.47%

TURNOVER0

P/E (TTM)1,750.00

% RANGE6.49%

EPS(TTM)0.0032

P/E(FORWARD)62.22

P/B67.96

BVPS0.0824

DIVIDEND--

P/S3.189

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP928.24M

SHARES OUTSTANDING172.43M

NEXT EARNINGS05/06-05/11

FREE FLOAT165.76M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

Reuters·03/23 11:31
Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services
TipRanks·03/19 08:40
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), CytomX Therapeutics (CTMX) and Johnson & Johnson (JNJ)
TipRanks·03/09 00:21
Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth
Reuters·03/04 22:29
Xeris Biopharma Chief Legal Officer and Corporate Secretary Beth Hecht Disposes of Common Shares
Seeking Alpha·03/04 12:29
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
TipRanks·03/03 15:50
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)
Dow Jones·03/02 17:44
Xeris Biopharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Seeking Alpha·03/02 17:08
Xeris rises on 2026 revenue guidance, Q4 top-line beat
TipRanks·03/02 17:00
Wall Street Analysts Are Bullish on Top Healthcare Picks
Seeking Alpha·03/02 15:58
Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121
TipRanks·03/02 14:30
Nasus Approaches Key Data Readout That Could Reshape the Multi Billion Dollar Epinephrine Market (NYSE: NSRX)
NASDAQ·03/02 14:30
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
Reuters·03/02 14:01
BRIEF-Xeris Biopharma Q4 Product Revenue USD 83.43 Million Versus. Ibes Estimate USD 82.3 Million
Dow Jones·03/02 13:33
Xeris Biopharma Shares Rise After Guidance Beats Expectations
TipRanks·03/02 12:17
Xeris Biopharma reports Q4 revenue 6c vs. (3c) last year

Same Industry

Name/Symbol

Change%

Price

McKesson

MCK

-0.39%

860.16

Biogen Inc

BIIB

-3.78%

183.84

AMGN

Shire

SHPG

0.00%

179.20

CELG-RT

Lilly Eli & Co

LLY

+0.96%

886.63

CELG

TXMD

Johnson & Johnson

JNJ

+0.51%

240.45

Abbvie Inc

ABBV

+1.78%

213.12

ZTS

GILD

Novo-Nordisk A/S

NVO

-0.99%

36.04

Bristol-Myers Squibb Co

BMY

-1.50%

58.54

ALXN

Pfizer

PFE

+2.70%

27.77

Sanofi FR

SNY

+0.34%

46.78

GCVRZ

NVS

Dr Reddys Labs

RDY

-2.11%

13.48

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.